pazopanib
Sponsor INTS · listed as INTS
READOUT
Phase 3
Confidence: medium
Source: clinicaltrials
Next catalyst
Event typeREADOUT
Expected date2026-12-30
As disclosedDec 30, 2026
Date precisionday
Confidencemedium
Trial & sponsor
Trial (NCT)NCT03592472
PhasePHASE3
StatusRECRUITING
Lead sponsorXynomic Pharmaceuticals, Inc.
Listed asINTS
Condition(s)Renal Cell Carcinoma
!
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This is one row of the free CSA sample. The full snapshot carries 2,103 forward catalysts across 139 listed sponsors.
Get the full dataset — $499 → More INTS catalysts